14 April 2025 – The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued recommendations addressing the vulnerabilities of the European Union (EU) in the supply chain of radiopharmaceuticals through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG). Such medicines contain radioactive forms of chemical elements called radioisotopes which are used to diagnose and treat medical conditions such as cancer. Their use is steadily increasing.

The production of such radiopharmaceuticals relies on stable isotopes and other materials which are mainly sourced from third countries. Additionally, the supply chain of these medicines, including how to transport them safely, is complex. The recommendations emphasise the need to increase the EU’s domestic capabilities through several initiatives.

For more information, see here.